Review Article

Open Access

Potential Role of iPSC Technology in Creating Exciting New Opportunities for Cardiovascular Research

Yuan Li*

National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Chaoyang, Beijing, China

Abstract

By providing structures to learn about the mechanisms of disease pathogenesis that should result in new therapies or reveal medication sensitivities, induced pluripotent stem cell (iPSC) technology is creating exciting new opportunities for cardiovascular research. The practical relevance of iPSC-derived cardiomyocytes in drug development and toxicity testing is explored in this study, with a focus on the advancements that have already been accomplished in this area. Additionally, it highlights the crucial steps that must be accomplished before this research may be widely applied in drug discovery and toxicological evaluations.

Keywords: [illegible]

Introduction

[illegible] 2011 [illegible] 2015, [illegible] 24-28% [illegible] [1,2] [illegible]

***Corresponding author:** Yuan Li, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Chaoyang, Beijing, China, E-mail: yuanli@gamil.com

Received: 01-Nov-2022, Manuscript No. wjpt-23-87414; **Editor assigned:** 03-Nov-2022, PreQC No. wjpt-23-87414(PQ); **Reviewed:** 17-Nov-2022, QC No. wjpt-23-87414; **Revised:** 22-Nov-2022, Manuscript No. wjpt-23-87414(R); **Published:** 29-Nov-2022, DOI: 10.4172/wjpt.1000172

Citation: Li Y (2022) Potential Role of iPSC Technology in Creating Exciting New Opportunities for Cardiovascular Research. World J Pharmacol Toxicol 5: 172.

[illegible]

[illegible]

Citation: Li Y (2022) Potential Role of iPSC Technology in Creating Exciting New Opportunities for Cardiovascular Research. World J Pharmacol Toxicol 5: 172.

of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet 6:557-568.

8. Dubois NC, Craft AM, Sharma P, Elliott DM, Stanley EG, et al. (2011) SIRPA is a specifc cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol 29:1011-1018.
9. Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, et al. (2012) Disease characterization using LQTS-specifc induced pluripotent stem cells. Cardiovasc Res 95:419-429.
10. Engler AJ, Carag-Krieger C, Johnson CP, Raab M, Tang HY, et al. (2008) Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: Scar-like rigidity inhibits beating. J Cell Sci 121:3794-3802.
11. Fatima G, Xu K, Shao S, Papadopoulos M, Lehmann JJ, et al. (2011) In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem 28:579-592.
12. Gonzalez F, Boue S, Izpisua Belmonte JC (2011)Methods for making induced pluripotent stem cells: Reprogramming a la carte. Nat Rev Genet 12:231-242.
13. Huber I, Itzhaki O, Caspi G, Arbel M, Tzukerman A, et al. (2007)Identifcation and selection of cardiomyocytes during human embryonic stem cell diferentiation. FASEB J, 21:2551-2563.
14. Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel G, et al.(2012) Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specifc human induced pluripotent stem cells. J Am Coll Cardiol 60:990-1000.
15. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, et al. (2010) A nonviral minicircle vector for deriving human iPS cells. Nat Methods 7:197-199.